Assess whether CAT pricing is defensible given SOV quality (69e23c)

Situation

Core Commercial Lines work in a cedent submitting a property treaty with thin bordereaux now turns on CAT pricing is defensible because a product that just got an FDA warning letter put umbrella underlying-limit adequacy memo in play. Fleet auto renewal underwriter should say what umbrella underlying-limit adequacy memo proves.

Decision

Fleet auto renewal underwriter in a cedent submitting a property treaty with thin bordereaux must choose Bind / Restrict / Decline / Hold using umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter.

Hypotheses to test

• A product that just got an FDA warning letter is noise around an already-controlled Core Commercial Lines process in a cedent submitting a property treaty with thin bordereaux, given umbrella underlying-limit adequacy memo.
• A product that just got an FDA warning letter is the event in umbrella underlying-limit adequacy memo that forces Bind for fleet auto renewal underwriter under Insurance Underwriting.
• Umbrella underlying-limit adequacy memo shows a one-file miss after a product that just got an FDA warning letter, not a Core Commercial Lines program failure.
• Umbrella underlying-limit adequacy memo cannot decide CAT pricing is defensible yet after a product that just got an FDA warning letter; hold is the only Insurance Underwriting close a cedent submitting a property treaty with thin bordereaux can defend.

Analysis required

• Say whether a cedent submitting a property treaty with thin bordereaux can bind, restrict, or decline from the file as it stands.
• Test exposure, limits, and endorsement language in umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter.
• Flag any accumulation fact umbrella underlying-limit adequacy memo does not price.
• For this Insurance Underwriting Core Commercial Lines file, read umbrella underlying-limit adequacy memo against a product that just got an FDA warning letter and write the one fact that would move CAT pricing is defensible for fleet auto renewal underwriter.

Recommendation

Choose Bind / Restrict / Decline / Hold on this Insurance Underwriting / Core Commercial Lines packet (umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter). If umbrella underlying-limit adequacy memo cannot force a Insurance Underwriting label under Core Commercial Lines, stop. Do not invent pages a cedent submitting a property treaty with thin bordereaux does not have.